NCT03698383: Phase II Study of Herzuma Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

NCT03698383
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: PI3K, PTEN, mTOR
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have breast tumor with suspected PI3K-pathway dependence; Patients must have had 2+ HER-2 directed therapy including trastuzumab for metastatic disease is mandatory
Exclusions: Patient has symptomatic & unstable CNS metastases- see trial for details; Patients with prior treatment of an mTOR or PI3K inhibitor
https://ClinicalTrials.gov/show/NCT03698383

Comments are closed.

Up ↑